Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;73(24):4675-4684.
doi: 10.1007/s00018-016-2316-9. Epub 2016 Jul 28.

Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive?

Affiliations
Review

Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive?

Janna A van Diepen et al. Cell Mol Life Sci. 2016 Dec.

Abstract

Diabetes strongly predisposes to cardiovascular disease (CVD), the leading cause of mortality in these patients, as well as in the entire population. Hyperglycemia is an important cardiovascular risk factor as shown by the observation that even transient periods of hyperglycemia, despite return to normoglycemia during follow-up, increase the risk for CVD, a phenomenon termed 'hyperglycemic memory'. The molecular mechanisms underlying this phenomenon remain largely unknown. As inflammation plays an important role in the pathogenesis of atherosclerosis, we propose that long-term functional reprogramming of monocytes and macrophages, induced by hyperglycemia, plays an important role in the phenomenon of hyperglycemic memory leading to cardiovascular complications in patients with diabetes. In this review, we discuss recent insights showing that innate immune cells possess the capacity to reprogram their function through epigenetically mediated rewiring of gene transcription, a process termed 'trained immunity'. The long-term reprogramming of monocytes can be induced by microbial as well as metabolic products, and involves a shift in cellular metabolism from oxidative phosphorylation to aerobic glycolysis. We hypothesize that hyperglycemia in diabetes patients induces long-term activation of monocytes and macrophages through similar mechanisms, thereby contributing to plaque development and subsequent macrovascular complications.

Keywords: Atherosclerosis; Diabetes; Epigenetics; Hyperglycemia; Inflammation; Metabolism; Trained immunity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic representation of the concept that hyperglycemia induces ‘trained immunity’ in monocytes. Initial stimulation of monocytes by hyperglycemic conditions (i.e., glucose or AGEs) induces epigenetic reprogramming of monocytes. The reprogramming of monocytes results in a long-term activated phenotype and increased response to a subsequent stimulus (e.g., oxLDL or cytokines). The more ‘aggressive’ proatherosclerotic response is characterized by, e.g., increased proinflammatory cytokine secretion and foam cell formation. AGE advanced glycation end products, Mf macrophage, Mo monocytes, oxLDL oxidized LDL

Similar articles

Cited by

References

    1. Ahlqvist E, van Zuydam NR, Groop LC, McCarthy MI. The genetics of diabetic complications. Nat Rev Nephrol. 2015;11:277–287. doi: 10.1038/nrneph.2015.37. - DOI - PubMed
    1. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005;5:379–387. doi: 10.2165/00129784-200505060-00005. - DOI - PubMed
    1. Mourad JJ, Le Jeune S. Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens Suppl. 2008;26:S7–S13. doi: 10.1097/01.hjh.0000334601.93875.f8. - DOI - PubMed
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes C, Complications Trial/Epidemiology of Diabetes I. Complications Study Research G Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653. doi: 10.1056/NEJMoa052187. - DOI - PMC - PubMed
    1. Group AC. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. doi: 10.1056/NEJMoa0802987. - DOI - PubMed

Publication types